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In 2004, we tested all patients with newly diagnosed
tuberculosis (TB) for HIV in Kiev City. The results were
compared to information from medical records of 2002,
when co-infection prevalence was 6.3%. Of 968 TB
patients, 98 (10.1%) were HIV infected. TB-HIV co-infection
is increasing, especially in injecting drug users. 
I
n Ukraine, the prevalence of HIV infection has been
increasing since the mid-1990s (1,2). By January 2005,
a total of 74,856 cases of HIV infection had officially been
registered (http://www.aidsalliance.kiev.ua/). The real
number of HIV infected persons may be much higher, an
estimated 330,000–410,000 in 2001 (>1% of adult popula-
tion) (3). 
An increase in HIV prevalence is usually closely fol-
lowed by an increase in tuberculosis (TB) (4). In Kiev
City, the number of TB patients registered for treatment
doubled from 629 in 1992 to 1,274 in 2004. This increase
is mainly explained by economic and social changes after
independence (August 1991), but the progressing HIV epi-
demic may also play a role in the increase in the number of
TB patients. 
In a previous study in Kiev City, we estimated the
prevalence of HIV infection in patients with newly diag-
nosed TB at 6.3% in 2002 (5). In this study, we assess the
prevalence of HIV infection ≈2 years later and compare
the results of the 2 studies. We also determine risk factors
for TB-HIV co-infection.
The Study
From March 2004 to February 2005, all patients with
newly diagnosed TB, who were >18 years of age and liv-
ing in Kiev City, and who had begun anti-TB chemothera-
py in the Kiev City TB Services were eligible for
inclusion. Patients were informed about the study, coun-
seled, and asked to participate. Basic information was col-
lected about all TB patients from medical records and by
interview. Reasons for not providing a blood sample for
HIV testing were also recorded. 
In Ukraine, TB diagnosis is made by smear and culture
examination. All persons with suspected TB are evaluated
by a committee of experts. TB is classified as pulmonary
TB bacteriologically confirmed (smear or culture posi-
tive), pulmonary TB bacteriologically not confirmed
(smear and culture negative or not done), and extrapul-
monary TB.
Blood samples were tested for HIV by using Genscreen
Plus HIV Ag-Ab (Bio-Rad Laboratories, Steenvoorde,
France). Confirmation of the test result was done by
Abbott IMx system HIV-1/-2 3rd Generation Plus (M/S
Abbott GmbH, Wiesbaden, Germany). We tried to retest
cases with an indeterminate HIV test result. TB patients
with a positive test result were referred to the Kiev Anti-
AIDS Centre.
We used SPSS 12.0 (SPSS Inc., Chicago, IL, USA) for
data analysis with t tests and χ2 tests. Differences at the α
= 5% level were regarded as significant. We examined pre-
dictive factors for HIV infection by logistic regression.
The results were compared to those of a study using med-
ical record information from patients newly diagnosed
with TB in Kiev City in 2002 (5).
The study was approved by the medical ethics commit-
tee of the Yanovskiy Institute of Phtisiology and
Pulmonology, Kiev City, Ukraine. Written informed con-
sent was obtained from all participants.
A total of 1,090 TB patients were included from the 9
TB clinics and hospitals in Kiev City. Of those 1,090 TB
patients, 4 (0.4%) could not be counseled because they
were too ill or intellectually impaired, 83 (7.6%) did not
provide informed consent, and 15 (1.4%) had to be exclud-
ed from the study, primarily because medical workers
could not obtain a blood sample. The 102 (9.4%) TB
patients who did not participate in the study were signifi-
cantly older than those included: mean ages, respectively,
45.4 and 39.1 years (p<0.001). Other characteristics were
not significantly different. 
Of the 988 TB patients tested for HIV infection, 33
(3.3%) had an initial indeterminate test result. Sixteen of
those were retested, 3 refused retesting, and 14 were not
approached. Of those retested, 12 tested negative, 1 tested
positive, and 3 again had an indeterminate test result. Thus,
968 TB patients with a definite HIV test result could be
included in the analysis. Of those, 98 (10.1%) were HIV
infected, 64 (65.3%) were identified in our study as HIV
infected, and 34 (34.7%) had received a diagnosis of HIV
infection from the Kiev Anti-AIDS Centre laboratory
before being referred to the TB services with suspected TB. 
Reported injecting drug use was the strongest inde-
pendent predictor for HIV infection (Table 1). Those
reporting injecting drug use were 31.4 times more likely to
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(95% confidence interval [CI] 17.4–56.9). Also, those who
had reported a sexually transmitted disease in the past 5
years were more often HIV infected (odds ratio [OR] 4.4,
95% CI 1.6–12.4). 
The prevalence of HIV infection among TB patients
significantly increased from 6.3% in 2002 to 10.1% from
March 2004 through February 2005 (p = 0.011) (Table 2).
The prevalence of HIV-infected TB patients who reported
injecting drug use increased from 1.8% of all tested
patients with newly diagnosed TB in 2002 to 5.8% in
March 2004 through February 2005. Thus, the main
increase in TB-HIV co-infection was attributable to an
increase in TB-HIV co-infected patients who reported
injecting drug use. A larger proportion of persons with a
positive HIV test result reported injecting drug use in 2004
(57.1%) than in 2002 (27.8%) (p = 0.003).
HIV co-infection prevalence may be slightly overesti-
mated in the 2002 study (5). In the study conducted
between March 2004 and February 2005, TB patients
included in the study were more frequently <50 years of
age (p<0.001). TB patients <50 years of age were more
frequently HIV infected. Both studies may therefore over-
estimate the prevalence of TB-HIV co-infection.
Conclusions
HIV infection increased in patients with newly diag-
nosed TB in Kiev City between 2002 and 2004. This find-
ing is in agreement with the increase in the number of
registered cases of HIV infection in Ukraine since 1995 (6). 
The main risk factor for being co-infected with HIV
was reported injecting drug use. In 2002, 62.5% of the TB
patients that reported injecting drug use were HIV infect-
ed and in 2004 this number was 66.7%. In Ukraine, the
HIV epidemic started in injecting drug users thus that the
main risk factor for HIV infection was injecting drug use
is not surprising. 
We used voluntary confidential HIV testing. Previous
studies have found that use of this testing method can
result in participation bias because those at higher risk of
infection are more likely not to contribute specimens
(7–11) or selection bias if clinicians encourage testing in
those they consider to be more at risk (5). Although
unlinked anonymous testing would have prevented these
problems, the TB physicians participating in the study
believed that using this strategy was not feasible. In our
study, 7.6% refused to provide informed consent. This
finding is comparable to researchers’ experiences in other
countries (7,11,12).
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locally produced HIV test with unknown specificity and
sensitivity. We do not know whether the estimated co-
infection prevalence is valid or if we are likely to underes-
timate the true co-infection prevalence. Even if the locally
produced HIV test did not correctly identify 12% of the
HIV-positive patients (sensitivity 88%), the prevalence of
TB-HIV co-infection was still significantly higher in 2004. 
In the 2002 study, the percentage of persons not tested
was high (38.0%), compared to a proportion of 10.5% in
the 2004 study. If we assume that no HIV infections exist-
ed among those not tested, the minimum HIV-infection
prevalence in the 2002 study is 3.9% and in the 2004 study
9.1%. No notable differences were identified between
those tested and those not tested in variables that were
strongly associated with HIV infection. In conclusion, TB-
HIV co-infection is increasing in Kiev City, especially in
injecting drug users.
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